報價延遲最少15分鐘:2026/10/23 07:18 EDT
盤前時段
|
||||
|
94.6 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
95.06
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.12/1.14
|
|
企業價值
21.11B
|
| 資產負債 |
|
每股賬面淨值
3.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
606.42M
|
|
每股收益
1.29
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products. |
